PBYI News and Press, Puma Biotechnology Inc From 11/02/23

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 2, 2023, following the release of its third quarter 2023 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma (Clinicaltrials.gov identifier NCT04555837) at the 20...

2023-09-29 17:07:10 ET Summary Puma Biotechnology's Q2 2023 earnings show stagnant revenue and tightening margins, raising concerns about its strategic positioning. The company has a favorable liquidity status with $74.4M in liquid assets and positive cash inflows, but a high debt...

2023-09-21 17:03:55 ET More on Puma Biotechnology Puma Biotechnology: Cheap But Quite Risky Puma Biotechnology lung cancer candidate IND cleared by FDA Seeking Alpha’s Quant Rating on Puma Biotechnology For further details see: Puma Biotech gra...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, for the treatment of patients with smal...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the “Company”), announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the hybrid H.C. Wainwright 25 th Annual Global Inve...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has been reviewed, and Puma can proceed with the clinical development of alisertib monotherapy for the treatmen...

2023-08-03 16:51:24 ET Puma Biotechnology press release ( NASDAQ: PBYI ): Q2 Non-GAAP EPS of $0.05 misses by $0.02 . Revenue of $54.6M (-8.2% Y/Y) beats by $2.87M . Sees Q3 2023 net product revenue of $51M to $53M, net income of $3M to $4M. Sees FY23 net pr...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023. Unless otherwise stated, all comparisons are for the second quarter of 2023 compared to the second quarter of 2022. Product revenue, net consists entir...